OM
DSGN icon

Opaleye Management’s Design Therapeutics DSGN Stock Holding History

Opaleye Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-205,000
Closed -$687K – 46
2024
Q2 		$687K Buy
205,000
+91,962
+81% +$358K 0.16% 48
2024
Q1 		$456K Buy
+113,038
New +$302K 0.1% 51

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Opaleye Management's DSGN Position: Q3 2024 in Review

Opaleye Management sold out of Design Therapeutics (DSGN) in Q3 2024, closing a stake of 205,000 shares — an estimated $687K sold.

Opaleye Management first reported a position in DSGN in Q1 2024 and held it in 2 quarters. The position peaked at $687K in Q2 2024. 100 funds tracked by Wall St. Rank hold DSGN as of Q3 2024.

  • Opaleye Management reported no remaining Design Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Opaleye Management sold 205,000 Design Therapeutics shares in Q3 2024, an estimated $687K.
  • Opaleye Management first reported a position in Design Therapeutics in Q1 2024 and held it in 2 quarters.
  • Opaleye Management's Design Therapeutics position peaked at $687K in Q2 2024.
  • 100 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2024.

Based on Opaleye Management's 13F filing for Q3 2024, filed 14 Nov 2024.